Cinkate envisions itself as a hybrid foreign/domestic pharmaceutical company.  By developing strong business skills in China and forming a vehicle for successful IP based drug development, Cinkate has cultivated a productive business model from a mostly theoretical concept over the past 10 years. A natural extension of this concept is for Cinkate to offer this "bridge" function to companies interested in entering the Chinese pharmaceutical market.

The ability of Cinkate to successfully develop and launch a state of the art new product (Airohua®) in China, defend its exclusivity status for six years, and negotiate the regulatory and marketing requirements for commercial profitability speaks solidly for this business model. Thus, the bridge concept was initiated at the early stage of drug development for Airohua®.

This bridge concept is now being expanded to include a broader group of drug products and to include drug products owned by Western companies, but are still in late stage development.    Cinkate and its partners see this concept as a powerful catalyst for drug development that will benefit both the companies owning these products as well as the citizens of China and the west; a true win-win..

© 2009 Cinkate Corporation.